Soficitinib
Based on 1 Customer Validation
Soficitinib (Compound 20) is a selective tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) inhibitor, with IC50 values of 0.5 nM and 1.2 nM, respectively. Soficitinib shows promise for research into autoimmune diseases (such as psoriasis, rheumatoid arthritis) and inflammatory diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.54%
- CAS 番号: 2574524-67-5
- 分子式: C18H21ClN8O
- 分子量:400.87
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
生物活性
製品説明
IC50 & Target
[1]|
JAK2 1.2 nM (IC50) |
Tyk2 0.5 nM (IC50) |
体外実験
Soficitinib inhibits TYK2 and JAK2 with IC50 values of 0.5 nM and 1.2 nM, respectively[1].
Soficitinib (24 h) inhibits IL-12-induced IFN-γ secretion in NK92 cells, with an IC50 value of 233 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 2574524-67-5
-
性状 Solid
-
分子量 400.87
-
分子式 C18H21ClN8O
-
Color White to off-white
-
SMILES
C[C@]12[C@](CN(C2)C(CC#N)=O)([H])CN(C3=NC(NC4=CN(C)N=C4)=NC=C3Cl)C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (249.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
純度とドキュメンテーション
-
データシート (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4946 mL | 12.4729 mL | 24.9457 mL | 62.3644 mL |
| 5 mM | 0.4989 mL | 2.4946 mL | 4.9891 mL | 12.4729 mL | |
| 10 mM | 0.2495 mL | 1.2473 mL | 2.4946 mL | 6.2364 mL | |
| 15 mM | 0.1663 mL | 0.8315 mL | 1.6630 mL | 4.1576 mL | |
| 20 mM | 0.1247 mL | 0.6236 mL | 1.2473 mL | 3.1182 mL | |
| 25 mM | 0.0998 mL | 0.4989 mL | 0.9978 mL | 2.4946 mL | |
| 30 mM | 0.0832 mL | 0.4158 mL | 0.8315 mL | 2.0788 mL | |
| 40 mM | 0.0624 mL | 0.3118 mL | 0.6236 mL | 1.5591 mL | |
| 50 mM | 0.0499 mL | 0.2495 mL | 0.4989 mL | 1.2473 mL | |
| 60 mM | 0.0416 mL | 0.2079 mL | 0.4158 mL | 1.0394 mL | |
| 80 mM | 0.0312 mL | 0.1559 mL | 0.3118 mL | 0.7796 mL | |
| 100 mM | 0.0249 mL | 0.1247 mL | 0.2495 mL | 0.6236 mL |